
Rare disease group challenges effectiveness of state drug price caps
State-mandated upper payment limits on prescription drugs have failed to lower out-of-pocket costs for patients, according to a new report from the Rare Access Action Project. The study argues these reimbursement caps disrupt supply chains rather than providing financial relief, particularly for those relying on rare disease therapies.













/https://i.s3.glbimg.com/v1/AUTH_b58693ed41d04a39826739159bf600a0/internal_photos/bs/2022/q/4/SVWTSkRpqdwq4sbeE7Mg/masseur-doing-seated-neck-massage-for-businesswoma-2021-08-29-19-39-06-utc-1-.jpg)









